FDA OK'd a new indication for Eli Lilly's Symbyax, a Zyprexa and Prozac combination therapy. Symbyax is now indicated for patients with treatment-resistant depression, in addition to its prior indication for bipolar depression.
Draft guidance indicates the regulator is open to using patient experience as criteria for chronic fatigue syndrome treatments.
The agency's move to limit the formulary for certain drug classes is dead.
The NYT reports that the data on gaming long-term memory is inconclusive.